SpringerProtocols: Abstract: Animal Models of Neurodegenerative Diseases

10. Animal Models of Neurodegenerative Diseases

By: Wendy Phillips³, Andrew Michell³, Harald Pruess³, Roger A. Barker³

Abstract

Full Text

Download PDF (344K)

Animal models of neurodegenerative disease are excellent tools for studying pathogenesis and therapies including cellular transplantation. In this chapter, we describe different models of Huntington’s disease and Parkinson’s disease, stereotactic surgery (used in creation of lesion models and transplantation) and finally transplantation studies in these models.

Affiliation(s): (3) Cambridge Centre for Brain Repair, University of Cambridge, E.D. Adrian Building, Forvie Site, 5b Bateman Street, CB2 2PY Cambridge, UK

Book Title: Neural Cell Transplantation: Methods and Protocols

Series: Methods in Molecular Biology | Volume: 549 | Pub. Date: Jun-01-2009 | Page Range: 137-155 | DOI: 10.1007/978-1-60327-931-4_10

Subject: Cell Biology

Key Words: Animal models - Neurodegenerative disease - Transplantation - Neural precursor cells - Huntington’s disease - Parkinson’s disease

References

Download References

1.	Bates, G., Harper, P., and Jones, L. (2002) Huntington’s Disease. 3rd edition, Oxford University Press, Oxford.

2.	The Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes The Huntington’s Disease Collaborative Research Group Cell 72, 971–983.

3.	Foltynie, T., Brayne, C., and Barker, R.A. (2002) The heterogeneity of idiopathic Parkinson’s disease J. Neurol. 249, 138–145.

4.	Fearnley, J.M. and Lees, A.J. (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity Brain 114, 2283–2301.

5.	Coyle, J.T. and Schwarcz, R. (1976) Lesion of striatal neurones with kainic acid provides a model for Huntington’s chorea Nature 263, 244–246.

6.	Beal, M.F., Ferrante, R.J., Swartz, K.J., and Kowall, N.W. (1991) Chronic quinolinic acid lesions in rats closely resemble Huntington’s disease J. Neurosci. 11, 1649–1659.

7.	Brouillet, E., Jacquard, C., Bizat, N., and Blum, D. (2005) 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington’s disease J. Neurochem. 95, 1521–1540.

8.	Goebel, H.H., Heipertz, R., Scholz, W., Iqbal, K., and Tellez-Nagel, I. (1978) Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies Neurology 28, 23–31.

9.	Jenkins, B.G., Koroshetz, W.J., Beal, M.F., and Rosen, B.R. (1993) Evidence for impairment of energy metabolism in vivo in Huntington’s disease using localized 1H NMR spectroscopy Neurology 43, 2689–2695.

10.	Tabrizi, S.J., Workman, J., Hart, P.E., Mangiarini, L., Mahal, A., Bates, G., et al (2000) Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse Ann. Neurol. 47, 80–86.

11.	Guidetti, P., Charles, V., Chen, E.Y., Reddy, P.H., Kordower, J.H., Whetsell, W.O., Jr., et al (2001) Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production Exp. Neurol. 169, 340–350.

12.	Brennan, W.A., Jr., Bird, E.D., and Aprille, J.R. (1985) Regional mitochondrial respiratory activity in Huntington’s disease brain J. Neurochem. 44, 1948–1950.

13.	Hansson, O., Petersen, A., Leist, M., Nicotera, P., Castilho, R.F., and Brundin, P. (1999) Transgenic mice expressing a Huntington’s disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity Proc. Natl Acad. Sci. USA 96, 8727–8732.

14.	Phillips, W., Morton, A.J., and Barker, R.A. (2005) Abnormalities of neurogenesis in the R6/2 mouse model of Huntington’s disease are attributable to the in vivo microenvironment J. Neurosci. 25, 11564–11576.

15.	Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C. et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice Cell 87, 493–506.

16.	Pavese, N., Andrews, T.C., Brooks, D.J., Ho, A.K., Rosser, A.E., Barker, R.A., et al (2003) Progressive striatal and cortical dopamine receptor dysfunction in Huntington’s disease: a PET study Brain 126, 1127–1135.

17.	Rosas, H.D., Koroshetz, W.J., Chen, Y.I., Skeuse, C., Vangel, M., Cudkowicz, M.E., et al (2003) Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis Neurology 60, 1615–1620.

18.	Telenius, H., Kremer, H.P., Theilmann, J., Andrew, S.E., Almqvist, E., Anvret, M., et al (1993) Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent Hum. Mol. Genet. 2, 1535–1540.

19.	Kempermann, G., Kuhn, H.G., and Gage, F.H. (1997) Genetic influence on neurogenesis in the dentate gyrus of adult mice Proc. Natl Acad. Sci. USA 94, 10409–10414.

20.	Shuttleworth, C.W. and Connor, J.A. (2001) Strain-dependent differences in calcium signaling predict excitotoxicity in murine hippocampal neurons J. Neurosci. 21, 4225–4236.

21.	Hockly, E., Cordery, P.M., Woodman, B., Mahal, A., Van, D.A., Blakemore, C., et al (2002) Environmental enrichment slows disease progression in R6/2 Huntington’s disease mice Ann. Neurol. 51, 235–242.

22.	MacDonald, M.E., Barnes, G., Srinidhi, J., Duyao, M.P., Ambrose, C.M., Myers, R.H., et al (1993) Gametic but not somatic instability of CAG repeat length in Huntington’s disease J. Med. Genet. 30, 982–986.

23.	Rubinsztein, D.C., Leggo, J., Coles, R., Almqvist, E., Biancalana, V., Cassiman, J.J., et al (1996) Phenotypic characterization of individuals with 30–40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36–39 repeats Am. J. Hum. Genet. 59, 16–22.

24.	Snell, R.G., MacMillan, J.C., Cheadle, J.P., Fenton, I., Lazarou, L.P., Davies, P., et al (1993) Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington’s disease Nat. Genet. 4, 393–397.

25.	Carter, R.J., Hunt, M.J., and Morton, A.J. (2000) Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington’s disease gene Mov. Disord. 15, 925–937.

26.	Kempermann, G., Kuhn, H.G., and Gage, F.H. (1997) More hippocampal neurons in adult mice living in an enriched environment Nature 386, 493–495.

27.	Menalled, L.B. (2005) Knock-in mouse models of Huntington’s disease NeuroRx 2, 465–470.

28.	Hamel, E., Goetz, I.E., and Roberts, E. (1981) Glutamic acid decarboxylase and gamma-aminobutyric acid in Huntington’s disease fibroblasts and other cultured cells, determined by a [3H]muscimol radioreceptor assay J. Neurochem. 37, 1032–1038.

29.	Saudou, F., Finkbeiner, S., Devys, D., and Greenberg, M.E. (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions Cell 95, 55–66.

30.	Jackson, G.R., Salecker, I., Dong, X., Yao, X., Arnheim, N., Faber, P.W., et al (1998) Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons Neuron 21, 633–642.

31.	Faber, P.W., Alter, J.R., MacDonald, M.E., and Hart, A.C. (1999) Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron Proc. Natl Acad. Sci. USA 96, 179–184.

32.	Karlovich, C.A., John, R.M., Ramirez, L., Stainier, D.Y., and Myers, R.M. (1998) Characterization of the Huntington’s disease (HD) gene homologue in the zebrafish Danio rerio Gene 217, 117–125.

33.	Miller, V.M., Nelson, R.F., Gouvion, C.M., Williams, A., Rodriguez-Lebron, E., Harper, S.Q., et al (2005) CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo J. Neurosci. 25, 9152–9161.

34.	Morton, A.J. and Leavens, W. (2000) Mice transgenic for the human Huntington’s disease mutation have reduced sensitivity to kainic acid toxicity Brain Res. Bull. 52, 51–59.

35.	Hickey, M.A. and Morton, A.J. (2000) Mice transgenic for the Huntington’s disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity J. Neurochem. 75, 2163–2171.

36.	Petersen, A., Chase, K., Puschban, Z., DiFiglia, M., Brundin, P., and Aronin, N. (2002) Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington’s disease Exp. Neurol. 175, 297–300.

37.	Zeron, M.M., Hansson, O., Chen, N., Wellington, C.L., Leavitt, B.R., Brundin, P. et al (2002) Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington’s disease Neuron 33, 849–860.

38.	Menalled, L.B. and Chesselet, M.F. (2002) Mouse models of Huntington’s disease Trends Pharmacol. Sci. 23, 32–39.

39.	Bates, G.P., Mangiarini, L., Mahal, A., and Davies, S.W. (1997) Transgenic models of Huntington’s disease Hum. Mol. Genet. 6, 1633–1637.

40.	Li, J.Y., Popovic, N., and Brundin, P. (2005) The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies NeuroRx 2, 447–464.

41.	Rubinsztein, D.C. (2002) Lessons from animal models of Huntington’s disease Trends Genet. 18, 202–209.

42.	Feany, M.B. and Bender, W.W. (2000) A Drosophila model of Parkinson’s disease Nature 404, 394–398.

43.	Lakso, M., Vartiainen, S., Moilanen, A.M., Sirvio, J., Thomas, J.H., Nass, R. et al (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein J. Neurochem. 86, 165–172.

44.	Kirik, D. and Bjorklund, A. (2003) Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors Trends Neurosci. 26, 386–392.

45.	Zigmond, M.J. and Stricker, E.M. (1972) Deficits in feeding behavior after intraventricular injection of 6-hydroxydopamine in rats Science. 177, 1211–1214.

46.	Barker, R.A. and Dunnett, S.B. (1999) Functional integration of neural grafts in Parkinson’s disease Nat. Neurosci. 2, 1047–1048.

47.	Sauer, H. and Oertel, W.H. (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat Neuroscience 59, 401–415.

48.	Ungerstedt, U. and Arbuthnott, G.W. (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system Brain Res. 24, 485–493.

49.	Dunnett, S.B., Hernandez, T.D., Summerfield, A., Jones, G.H., and Arbuthnott, G. (1988) Graft-derived recovery from 6-OHDA lesions: specificity of ventral mesencephalic graft tissues Exp. Brain Res. 71, 411–424.

50.	Barker, R. and Dunnett, S.B. (1994) Ibotenic acid lesions of the striatum reduce drug-induced rotation in the 6-hydroxydopamine-lesioned rat Exp. Brain Res. 101, 365–374.

51.	Iancu, R., Mohapel, P., Brundin, P., and Paul, G. (2005) Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson’s disease in mice Behav. Brain Res. 162, 1–10.

52.	Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., et al (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders Science 287, 1265–1269.

53.	van der Putten, H., Wiederhold, K.H., Probst, A., Barbieri, S., Mistl, C., Danner, S., et al (2000) Neuropathology in mice expressing human alpha-synuclein J. Neurosci. 20, 6021–6029.

54.	Giasson, B.I., Duda, J.E., Quinn, S.M., Zhang, B., Trojanowski, J.Q., and Lee, V.M. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein Neuron 34, 521–533.

55.	Lee, M.K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A.S., et al (2002) Human alpha-synuclein-harboring familial Parkinson’s disease-linked Ala-53 Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice Proc. Natl Acad. Sci. USA 99, 8968–8973.

56.	Fernagut, P.O. and Chesselet, M.F. (2004) Alpha-synuclein and transgenic mouse models Neurobiol. Dis. 17, 123–130.

57.	Stein, T.D. and Johnson, J.A. (2002) Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways J. Neurosci. 22, 7380–7388.

58.	Rochet, J.C., Conway, K.A., and Lansbury, P.T., Jr. (2000) Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein Biochemistry 39, 10619–10626.

59.	Dobrossy, M.D. and Dunnett, S.B. (2005) Optimising plasticity: environmental and training associated factors in transplant-mediated brain repair Rev. Neurosci. 16, 1–21.

60.	Watts, C., Caldwell, M.A., and Dunnett, S.B. (1998) The development of intracerebral cell-suspension implants is influenced by the grafting medium Cell Transplant. 7, 573–583.

61.	Johann, V., Schiefer, J., Sass, C., Mey, J., Brook, G., Kruttgen, A., et al (2007) Time of transplantation and cell preparation determine neural stem cell survival in a mouse model of Huntington’s disease Exp. Brain Res. 177, 458–470.

62.	Watts, C., McNamara, I.R., and Dunnett, S.B. (2000) Volume and differentiation of striatal grafts in rats: relationship to the number of cells implanted Cell Transplant. 9, 65–72.

63.	O’ Keeffe, G.W. and Sullivan, A.M. (2005) Donor age affects differentiation of rat ventral mesencephalic stem cells Neurosci. Lett. 375, 101–106.

64.	Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., et al (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo Cell 90, 549–558.

65.	Harvey, A.R., Symons, N.A., Pollett, M.A., Brooker, G.J., and Bartlett, P.F. (1997) Fate of adult neural precursors grafted to adult cortex monitored with a Y-chromosome marker Neuroreport 8, 3939–3943.

66.	Miller, M.W. and Nowakowski, R.S. (1988) Use of bromodeoxyuridine-immunohistochemistry to examine the proliferation, migration and time of origin of cells in the central nervous system Brain Res. 457, 44–52.

67.	Caldwell, M.A., He, X., and Svendsen, C.N. (2005) 5-Bromo-2’-deoxyuridine is selectively toxic to neuronal precursors in vitro Eur. J. Neurosci. 22, 2965–2970.

68.	Christie, B.R. and Cameron, H.A. (2006) Neurogenesis in the adult hippocampus Hippocampus 16, 199–207.

69.	Bull, N.D. and Bartlett, P.F. (2005) The adult mouse hippocampal progenitor is neurogenic but not a stem cell J. Neurosci. 25, 10815–10821.

70.	Burns, T.C., Ortiz-Gonzalez, X.R., Gutierrez-Perez, M., Keene, C.D., Sharda, R., Demorest, Z.L., et al (2006) Thymidine analogs are transferred from prelabeled donor to host cells in the central nervous system after transplantation: a word of caution Stem Cells 24, 1121–1127.

71.	Hendriks, W.T., Ruitenberg, M.J., Blits, B., Boer, G.J., and Verhaagen, J. (2004) Viral vector-mediated gene transfer of neurotrophins to promote regeneration of the injured spinal cord Prog. Brain Res. 146, 451–476.

72.	Follenzi, A. and Naldini, L. (2002) HIV-based vectors. Preparation and use Methods Mol. Med. 69, 259–274.

73.	Lewis, P.F. and Emerman, M. (1994) Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus J. Virol. 68, 510–516.

74.	Liu, Y., Himes, B.T., Solowska, J., Moul, J., Chow, S.Y., Park, K.I., et al (1999) Intraspinal delivery of neurotrophin-3 using neural stem cells genetically modified by recombinant retrovirus Exp. Neurol. 158, 9–26.

75.	Limke, T.L. and Rao, M.S. (2002) Neural stem cells in aging and disease J. Cell Mol. Med. 6, 475–496.

76.	Watts, C. and Dunnett, S.B. (1998) Effects of severity of host striatal damage on the morphological development of intrastriatal transplants in a rodent model of Huntington’s disease: implications for timing of surgical intervention J. Neurosurg. 89, 267–274.

77.	Svendsen, C.N., ter Borg, M.G., Armstrong, R.J., Rosser, A.E., Chandran, S., Ostenfeld, T., et al (1998) A new method for the rapid and long term growth of human neural precursor cells J. Neurosci. Methods 85, 141–152.

Comments (Loading...)

Post comment/View all comments